Use of angiotensin‑converting enzyme inhibitors in gynecological cancers: Pathways and mechanisms involved (Review)
- Authors:
- Roland Frederik Lengkey
- Ray Sebastian Soetadji
- Ardo Sanjaya
-
Affiliations: Department of Obstetrics and Gynecology, Unggul Karsa Medika Hospital, Maranatha Christian University, Bandung, West Java 40218, Indonesia, Undergraduate Program in Medicine, Faculty of Medicine, Maranatha Christian University, Bandung, West Java 40164, Indonesia, Department of Anatomy, Faculty of Medicine, Maranatha Christian University, Bandung, West Java 40164, Indonesia - Published online on: July 8, 2024 https://doi.org/10.3892/wasj.2024.263
- Article Number: 48
-
Copyright : © Lengkey et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY 4.0].
This article is mentioned in:
Abstract
 |
|
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Stewart SL, Lakhani N, Brown PM, Larkin OA, Moore AR and Hayes NS: Gynecologic cancer prevention and control in the national comprehensive cancer control program: Progress, current activities, and future directions. J Womens Health (Larchmt). 22:651–657. 2013.PubMed/NCBI View Article : Google Scholar | |
|
La Vecchia C: Ovarian cancer: Epidemiology and risk factors. Eur J Cancer Prev. 26:55–62. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Crosbie EJ, Kitson SJ, McAlpine JN, Mukhopadhyay A, Powell ME and Singh N: Endometrial cancer. Lancet. 399:1412–1428. 2022.PubMed/NCBI View Article : Google Scholar | |
|
Hassani B, Attar Z and Firouzabadi N: The renin-angiotensin- aldosterone system (RAAS) signaling pathways and cancer: Foes versus allies. Cancer Cell Int. 23(254)2023.PubMed/NCBI View Article : Google Scholar | |
|
George AJ, Thomas WG and Hannan RD: The renin-angiotensin system and cancer: Old dog, new tricks. Nat Rev Cancer. 10:745–759. 2010.PubMed/NCBI View Article : Google Scholar | |
|
Zhao Y, Wang H, Li X, Cao M, Lu H, Meng Q, Pang H, Li H, Nadolny C, Dong X and Cai L: Ang II-AT1R increases cell migration through PI3K/AKT and NF-κB pathways in breast cancer. J Cell Physiol. 229:1855–1862. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Rasha F, Ramalingam L, Gollahon L, Rahman RL, Rahman SM, Menikdiwela K and Moustaid-Moussa N: Mechanisms linking the renin-angiotensin system, obesity, and breast cancer. Endocr Relat Cancer. 26:R653–R672. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Coulson R, Liew SH, Connelly AA, Yee NS, Deb S, Kumar B, Vargas AC, O'Toole SA, Parslow AC, Poh A, et al: The angiotensin receptor blocker, Losartan, inhibits mammary tumor development and progression to invasive carcinoma. Oncotarget. 8:18640–18656. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Pei N, Mao Y, Wan P, Chen X, Li A, Chen H, Li J, Wan R, Zhang Y, Du H, et al: Angiotensin II type 2 receptor promotes apoptosis and inhibits angiogenesis in bladder cancer. J Exp Clin Cancer Res. 36(77)2017.PubMed/NCBI View Article : Google Scholar | |
|
Chen X, Meng Q, Zhao Y, Liu M, Li D, Yang Y, Sun L, Sui G, Cai L and Dong X: Angiotensin II type 1 receptor antagonists inhibit cell proliferation and angiogenesis in breast cancer. Cancer Lett. 328:318–324. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Almutlaq M, Alamro AA, Alamri HS, Alghamdi AA and Barhoumi T: The effect of local renin angiotensin system in the common types of cancer. Front Endocrinol (Lausanne). 12(736361)2021.PubMed/NCBI View Article : Google Scholar | |
|
Okwan-Duodu D, Landry J, Shen XZ and Diaz R: Angiotensin-converting enzyme and the tumor microenvironment: Mechanisms beyond angiogenesis. Am J Physiol Regul Integr Comp Physiol. 305:R205–R215. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Fan F, Tian C, Tao L, Wu H, Liu Z, Shen C, Jiang G and Lu Y: Candesartan attenuates angiogenesis in hepatocellular carcinoma via downregulating AT1R/VEGF pathway. Biomed Pharmacother. 83:704–711. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Hanahan D: Hallmarks of cancer: New dimensions. Cancer Discov. 12:31–46. 2022.PubMed/NCBI View Article : Google Scholar | |
|
Nguyen NTH, Nguyen PA, Huang CW, Wang CH, Lin MC, Hsu MH, Bao HB, Chien SC and Yang HC: Renin-angiotensin-aldosterone system inhibitors and development of gynecologic cancers: A 23 million individual population-based study. Int J Mol Sci. 24(3814)2023.PubMed/NCBI View Article : Google Scholar | |
|
Lee SH, Park J, Park RW, Shin SJ, Kim J, Sung JD, Kim DJ and Yang K: Renin-angiotensin-aldosterone system inhibitors and risk of cancer: A population-based cohort study using a common data model. Diagnostics. 12(263)2022.PubMed/NCBI View Article : Google Scholar | |
|
Wang Z, Wei L, Yin C, Li W and Wan B: Angiotensin receptor blocker associated with a decreased risk of lung cancer: An updated meta-analysis. J Pers Med. 13(243)2023.PubMed/NCBI View Article : Google Scholar | |
|
Christian JB, Lapane KL, Hume AL, Eaton CB and Weinstock MA: VATTC Trial. Association of ACE inhibitors and angiotensin receptor blockers with keratinocyte cancer prevention in the randomized VATTC trial. J Natl Cancer Inst. 100:1223–1232. 2008.PubMed/NCBI View Article : Google Scholar | |
|
Chiang YY, Chen KB, Tsai TH and Tsai WC: Lowered cancer risk with ACE inhibitors/ARBs: A population-based cohort study. J Clin Hypertens (Greenwich). 16:27–33. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Yarmolinsky J, Díez-Obrero V, Richardson TG, Pigeyre M, Sjaarda J, Paré G, Walker VM, Vincent EE, Tan VY, Obón-Santacana M, et al: Genetically proxied therapeutic inhibition of antihypertensive drug targets and risk of common cancers: A mendelian randomization analysis. PLoS Med. 19(e1003897)2022.PubMed/NCBI View Article : Google Scholar | |
|
Copland E, Canoy D, Nazarzadeh M, Bidel Z, Ramakrishnan R, Woodward M, Chalmers J, Teo KK, Pepine CJ, Davis BR, et al: Antihypertensive treatment and risk of cancer: An individual participant data meta-analysis. Lancet Oncol. 22:558–570. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Wang S, Xie L, Zhuang J, Qian Y, Zhang G, Quan X, Li L, Yu H, Zhang W, Zhao W and Qian B: Association between use of antihypertensive drugs and the risk of cancer: A population-based cohort study in Shanghai. BMC Cancer. 23(425)2023.PubMed/NCBI View Article : Google Scholar | |
|
Chen X, Yi CH and Ya KG: Renin-angiotensin system inhibitor use and colorectal cancer risk and mortality: A dose-response meta analysis. J Renin Angiotensin Aldosterone Syst. 21(1470320319895646)2020.PubMed/NCBI View Article : Google Scholar | |
|
Sipahi I: Risk of cancer with angiotensin-receptor blockers increases with increasing cumulative exposure: Meta-regression analysis of randomized trials. PLoS One. 17(e0263461)2022.PubMed/NCBI View Article : Google Scholar | |
|
Murphy JE, Wo JY, Ryan DP, Clark JW, Jiang W, Yeap BY, Drapek LC, Ly L, Baglini CV, Blaszkowsky LS, et al: Total neoadjuvant therapy with FOLFIRINOX in combination with losartan followed by chemoradiotherapy for locally advanced pancreatic cancer: A phase 2 clinical trial. JAMA Oncol. 5:1020–1027. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Uemura H, Hasumi H, Kawahara T, Sugiura S, Miyoshi Y, Nakaigawa N, Teranishi J, Noguchi K, Ishiguro H and Kubota Y: Pilot study of angiotensin II receptor blocker in advanced hormone-refractory prostate cancer. Int J Clin Oncol. 10:405–410. 2005.PubMed/NCBI View Article : Google Scholar | |
|
Passos-Silva DG, Verano-Braga T and Santos RAS: Angiotensin-(1-7): Beyond the cardio-renal actions. Clin Sci (Lond). 124:443–456. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Flores-Munoz M, Work LM, Douglas K, Denby L, Dominiczak AF, Graham D and Nicklin SA: Angiotensin-(1-9) attenuates cardiac fibrosis in the stroke-prone spontaneously hypertensive rat via the angiotensin type 2 receptor. Hypertension. 59:300–307. 2012.PubMed/NCBI View Article : Google Scholar | |
|
Wichmann IA and Cuello MA: Obesity and gynecological cancers: A toxic relationship. Int J Gynaecol Obstet. 155 (Suppl 1):S123–S134. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Liu Y, Yang J, Hilliard TS, Wang Z, Johnson J, Wang W, Harper EI, Ott C, O'Brien C, Campbell L, et al: Host obesity alters the ovarian tumor immune microenvironment and impacts response to standard of care chemotherapy. J Exp Clin Cancer Res. 42(165)2023.PubMed/NCBI View Article : Google Scholar | |
|
Cabandugama PK, Gardner MJ and Sowers JR: The renin angiotensin aldosterone system in obesity and hypertension: Roles in the cardiorenal metabolic syndrome. Med Clin North Am. 101:129–137. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Thethi T, Kamiyama M and Kobori H: The link between the renin-angiotensin-aldosterone system and renal injury in obesity and the metabolic syndrome. Curr Hypertens Rep. 14:160–169. 2012.PubMed/NCBI View Article : Google Scholar | |
|
Boustany CM, Bharadwaj K, Daugherty A, Brown DR, Randall DC and Cassis LA: Activation of the systemic and adipose renin-angiotensin system in rats with diet-induced obesity and hypertension. Am J Physiol Regul Integr Comp Physiol. 287:R943–R949. 2004.PubMed/NCBI View Article : Google Scholar | |
|
Schütten MTJ, Houben AJHM, De Leeuw PW and Stehouwer CDA: The link between adipose tissue renin-angiotensin-aldosterone system signaling and obesity-associated hypertension. Physiology (Bethesda). 32:197–209. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Yiannikouris F, Gupte M, Putnam K, Thatcher S, Charnigo R, Rateri DL, Daugherty A and Cassis LA: Adipocyte deficiency of angiotensinogen prevents obesity-induced hypertension in male mice. Hypertension. 60:1524–1530. 2012.PubMed/NCBI View Article : Google Scholar | |
|
Yvan-Charvet L, Even P, Bloch-Faure M, Guerre-Millo M, Moustaid-Moussa N, Ferre P and Quignard-Boulange A: Deletion of the angiotensin type 2 receptor (AT2R) reduces adipose cell size and protects from diet-induced obesity and insulin resistance. Diabetes. 54:991–999. 2005.PubMed/NCBI View Article : Google Scholar | |
|
Han H, Guo W, Shi W, Yu Y, Zhang Y, Ye X and He J: Hypertension and breast cancer risk: A systematic review and meta-analysis. Sci Rep. 7(44877)2017.PubMed/NCBI View Article : Google Scholar | |
|
Sun LM, Kuo HT, Jeng LB, Lin CL, Liang JA and Kao CH: Hypertension and subsequent genitourinary and gynecologic cancers risk: A population-based cohort study. Medicine (Baltimore). 94(e753)2015.PubMed/NCBI View Article : Google Scholar | |
|
Lindgren AM, Nissinen AM, Tuomilehto JO and Pukkala E: Cancer pattern among hypertensive patients in North Karelia, Finland. J Hum Hypertens. 19:373–379. 2005.PubMed/NCBI View Article : Google Scholar | |
|
Cibula D, Raspollini MR, Planchamp F, Centeno C, Chargari C, Felix A, Fischerová D, Jahnn-Kuch D, Joly F, Kohler C, et al: ESGO/ESTRO/ESP guidelines for the management of patients with cervical cancer-update 2023. Int J Gynecol Cancer. 33:649–666. 2023.PubMed/NCBI View Article : Google Scholar | |
|
Oaknin A, Bosse TJ, Creutzberg CL, Giornelli G, Harter P, Joly F, Lorusso D, Marth C, Makker V, Mirza MR, et al: Endometrial cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 33:860–877. 2022.PubMed/NCBI View Article : Google Scholar | |
|
Colombo N, Sessa C, Du Bois A, Ledermann J, McCluggage WG, McNeish I, Morice P, Pignata S, Ray-Coquard I, Vergote I, et al: ESMO-ESGO consensus conference recommendations on ovarian cancer: Pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. Ann Oncol. 30:672–705. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Gil-Ibanez B, Davies-Oliveira J, Lopez G, Díaz-Feijoo B, Tejerizo-Garcia A and Sehouli J: Impact of gynecological cancers on health-related quality of life: Historical context, measurement instruments, and current knowledge. Int J Gynecol Cancer. 33:1800–1806. 2023.PubMed/NCBI View Article : Google Scholar | |
|
Graham SV: The human papillomavirus replication cycle, and its links to cancer progression: A comprehensive review. Clin Sci (Lond). 131:2201–2221. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Balasubramaniam SD, Balakrishnan V, Oon CE and Kaur G: Key molecular events in cervical cancer development. Medicina (Kaunas). 55(384)2019.PubMed/NCBI View Article : Google Scholar | |
|
Kurnia I, Rauf S, Hatta M, Arifuddin S, Hidayat YM, Natzir R, Kaelan C, Bukhari A, Pelupessy NU and Patelonggi IJ: Molecular Patho-mechanisms of cervical cancer (MMP1). Ann Med Surg (Lond). 77(103415)2022.PubMed/NCBI View Article : Google Scholar | |
|
Park JS, Kim EJ, Kwon HJ, Hwang ES, Namkoong SE and Um SJ: Inactivation of interferon regulatory factor-1 tumor suppressor protein by HPV E7 oncoprotein. Implication for the E7-mediated immune evasion mechanism in cervical carcinogenesis. J Biol Chem. 275:6764–6769. 2000.PubMed/NCBI View Article : Google Scholar | |
|
Ashrafi GH, Haghshenas MR, Marchetti B, O'Brien PM and Campo MS: E5 protein of human papillomavirus type 16 selectively downregulates surface HLA class I. Int J Cancer. 113:276–283. 2005.PubMed/NCBI View Article : Google Scholar | |
|
Bhattacharjee R, Das SS, Biswal SS, Nath A, Das D, Basu A, Malik S, Kumar L, Kar S, Singh SK, et al: Mechanistic role of HPV-associated early proteins in cervical cancer: Molecular pathways and targeted therapeutic strategies. Crit Rev Oncol Hematol. 174(103675)2022.PubMed/NCBI View Article : Google Scholar | |
|
Burd EM: Human papillomavirus and cervical cancer. Clin Microbiol Rev. 16:1–17. 2003.PubMed/NCBI View Article : Google Scholar | |
|
Pal A and Kundu R: Human papillomavirus E6 and E7: The cervical cancer hallmarks and targets for therapy. Front Microbiol. 10(3116)2020.PubMed/NCBI View Article : Google Scholar | |
|
Gius D, Funk MC, Chuang EY, Feng S, Huettner PC, Nguyen L, Bradbury CM, Mishra M, Gao S, Buttin BM, et al: Profiling microdissected epithelium and stroma to model genomic signatures for cervical carcinogenesis accommodating for covariates. Cancer Res. 67:7113–7123. 2007.PubMed/NCBI View Article : Google Scholar | |
|
Vats A, Trejo-Cerro O, Thomas M and Banks L: Human papillomavirus E6 and E7: What remains? Tumour Virus Res. 11(200213)2021.PubMed/NCBI View Article : Google Scholar | |
|
Lee JE, Chung Y, Rhee S and Kim TH: Untold story of human cervical cancers: HPV-negative cervical cancer. BMB Rep. 55:429–438. 2022.PubMed/NCBI View Article : Google Scholar | |
|
Nicolás I, Marimon L, Barnadas E, Saco A, Rodríguez-Carunchio L, Fusté P, Martí C, Rodriguez-Trujillo A, Torne A, Del Pino M and Ordi J: HPV-negative tumors of the uterine cervix. Mod Pathol. 32:1189–1196. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Zampronha Rde AC, Freitas-Junior R, Murta EFC, Michelin MA, Barbaresco AA, Adad SJ, de Oliveira AM, Rassi AB and Oton GJB: Human papillomavirus types 16 and 18 and the prognosis of patients with stage I cervical cancer. Clinics (Sao Paulo). 68:809–814. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Lu KH and Broaddus RR: Endometrial cancer. N Engl J Med. 383:2053–2064. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Makker V, MacKay H, Ray-Coquard I, Levine DA, Westin SN, Aoki D and Oaknin A: Endometrial cancer. Nat Rev Dis Primers. 7(88)2021.PubMed/NCBI View Article : Google Scholar | |
|
Crosbie EJ, Zwahlen M, Kitchener HC, Egger M and Renehan AG: Body mass index, hormone replacement therapy, and endometrial cancer risk: A meta-analysis. Cancer Epidemiol Biomarkers Prev. 19:3119–3130. 2010.PubMed/NCBI View Article : Google Scholar | |
|
Aune D, Navarro Rosenblatt DA, Chan DSM, Vingeliene S, Abar L, Vieira AR, Greenwood DC, Bandera EV and Norat T: Anthropometric factors and endometrial cancer risk: A systematic review and dose-response meta-analysis of prospective studies. Ann Oncol. 26:1635–1648. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Renehan AG, Soerjomataram I, Tyson M, Egger M, Zwahlen M, Coebergh JW and Buchan I: Incident cancer burden attributable to excess body mass index in 30 European countries. Int J Cancer. 126:692–702. 2010.PubMed/NCBI View Article : Google Scholar | |
|
Yu K, Huang ZY, Xu XL, Li J, Fu XW and Deng SL: Estrogen receptor function: Impact on the human endometrium. Front Endocrinol (Lausanne). 13(827724)2022.PubMed/NCBI View Article : Google Scholar | |
|
Joshi A and Ellenson LH: PI3K/PTEN/AKT genetic mouse models of endometrial carcinoma. Adv Exp Med Biol. 943:261–273. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Terzic M, Aimagambetova G, Kunz J, Bapayeva G, Aitbayeva B, Terzic S and Laganà AS: Molecular basis of endometriosis and endometrial cancer: Current knowledge and future perspectives. Int J Mol Sci. 22(9274)2021.PubMed/NCBI View Article : Google Scholar | |
|
Ebring C, Marlin R, Macni J, Vallard A, Bergerac S, Beaubrun-Renard M, Joachim C and Jean-Laurent M: Type II endometrial cancer: Incidence, overall and disease-free survival in Martinique. PLoS One. 18(e0278757)2023.PubMed/NCBI View Article : Google Scholar | |
|
Ohgami T and Kato K: Pathogenesis of endometrial cancer. In: Current Approaches to Endometrial Cancer. Future Medicine Ltd, Unitec House, 2 Albert Place, London N3 1QB, UK, pp18-32, 2014. | |
|
Miyamoto T and Shiozawa T: Two-sided role of estrogen on endometrial carcinogenesis: stimulator or suppressor? Gynecol Endocrinol. 35:370–375. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Lobo FD and Thomas E: Type II endometrial cancers: A case series. J Midlife Health. 7:69–72. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Shen F, Gao Y, Ding J and Chen Q: Is the positivity of estrogen receptor or progesterone receptor different between type 1 and type 2 endometrial cancer? Oncotarget. 8:506–511. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Cancer Genome Atlas Research Network: Integrated genomic analyses of ovarian carcinoma. Nature. 474:609–615. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Testing strategies for Lynch syndrome in people with endometrial cancer. Diagnostics guidance, 2020. | |
|
Stinton C, Jordan M, Fraser H, Auguste P, Court R, Al-Khudairy L, Madan J, Grammatopoulos D and Taylor-Phillips S: Testing strategies for Lynch syndrome in people with endometrial cancer: Systematic reviews and economic evaluation. Health Technol Assess. 25:1–216. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Liu Y, Patel L, Mills GB, Lu KH, Sood AK, Ding L, Kucherlapati R, Mardis ER, Levine DA, Shmulevich I, et al: Clinical significance of CTNNB1 mutation and Wnt pathway activation in endometrioid endometrial carcinoma. J Natl Cancer Inst. 106(dju245)2014.PubMed/NCBI View Article : Google Scholar | |
|
Kurnit KC, Kim GN, Fellman BM, Urbauer DL, Mills GB, Zhang W and Broaddus RR: CTNNB1 (beta-catenin) mutation identifies low grade, early stage endometrial cancer patients at increased risk of recurrence. Mod Pathol. 30:1032–1041. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Prat J: Ovarian carcinomas: Five distinct diseases with different origins, genetic alterations, and clinicopathological features. Virchows Arch. 460:237–249. 2012.PubMed/NCBI View Article : Google Scholar | |
|
Lheureux S, Gourley C, Vergote I and Oza AM: Epithelial ovarian cancer. Lancet. 393:1240–1253. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Hollis RL: Molecular characteristics and clinical behaviour of epithelial ovarian cancers. Cancer Lett. 555(216057)2023.PubMed/NCBI View Article : Google Scholar | |
|
Irodi A, Rye T, Herbert K, Churchman M, Bartos C, Mackean M, Nussey F, Herrington CS, Gourley C and Hollis RL: Patterns of clinicopathological features and outcome in epithelial ovarian cancer patients: 35 Years of prospectively collected data. BJOG. 127:1409–1420. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Patch AM, Christie EL, Etemadmoghadam D, Garsed DW, George J, Fereday S, Nones K, Cowin P, Alsop K, Bailey PJ, et al: Whole-genome characterization of chemoresistant ovarian cancer. Nature. 521:489–494. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Lheureux S, Braunstein M and Oza AM: Epithelial ovarian cancer: Evolution of management in the era of precision medicine. CA Cancer J Clin. 69:280–304. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Oza AM, Tinker AV, Oaknin A, Shapira-Frommer R, McNeish IA, Swisher EM, Ray-Coquard I, Bell-McGuinn K, Coleman RL, O'Malley DM, et al: Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2. Gynecol Oncol. 147:267–275. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Boehm KM, Aherne EA, Ellenson L, Nikolovski I, Alghamdi M, Vázquez-García I, Zamarin D, Long Roche K, Liu Y, Patel D, et al: Multimodal data integration using machine learning improves risk stratification of high-grade serous ovarian cancer. Nat Cancer. 3:723–733. 2022.PubMed/NCBI View Article : Google Scholar | |
|
Li W, Liu Y, Liu W, Tang ZR, Dong S, Li W, Zhang K, Xu C, Hu Z, Wang H, et al: Machine learning-based prediction of lymph node metastasis among osteosarcoma patients. Front Oncol. 12(797103)2022.PubMed/NCBI View Article : Google Scholar | |
|
Bahar ME, Kim HJ and Kim DR: Targeting the RAS/RAF/MAPK pathway for cancer therapy: From mechanism to clinical studies. Signal Transduct Target Ther. 8(455)2023.PubMed/NCBI View Article : Google Scholar | |
|
Patel S, Rauf A, Khan H and Abu-Izneid T: Renin-angiotensin-aldosterone (RAAS): The ubiquitous system for homeostasis and pathologies. Biomed Pharmacother. 94:317–325. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Martyniak A and Tomasik PJ: A new perspective on the renin-angiotensin system. Diagnostics (Basel). 13(16)2022.PubMed/NCBI View Article : Google Scholar | |
|
Mirabito Colafella KM, Bovée DM and Danser AHJ: The renin-angiotensin-aldosterone system and its therapeutic targets. Exp Eye Res. 186(107680)2019.PubMed/NCBI View Article : Google Scholar | |
|
Fountain JH, Kaur J and Lappin SL: Physiology, renin angiotensin system. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing, 2024. | |
|
Sequeira-Lopez MLS and Gomez RA: Renin cells, the kidney, and hypertension. Circ Res. 128:887–907. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Lu H, Cassis LA, Kooi CWV and Daugherty A: Structure and functions of angiotensinogen. Hypertens Res. 39:492–500. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Mascolo A, Scavone C, Rafaniello C, De Angelis A, Urbanek K, di Mauro G, Cappetta D, Berrino L, Rossi F and Capuano A: The role of renin-angiotensin-aldosterone system in the heart and lung: Focus on COVID-19. Front Pharmacol. 12(667254)2021.PubMed/NCBI View Article : Google Scholar | |
|
Kawai T, Forrester SJ, O'Brien S, Baggett A, Rizzo V and Eguchi S: AT1 receptor signaling pathways in the cardiovascular system. Pharmacol Res. 125:4–13. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Maranduca MA, Clim A, Pinzariu AC, Statescu C, Sascau RA, Tanase DM, Serban DN, Branisteanu DC, Branisteanu DE, Huzum B and Serban IL: Role of arterial hypertension and angiotensin II in chronic kidney disease (review). Exp Ther Med. 25(153)2023.PubMed/NCBI View Article : Google Scholar | |
|
Sun Y, Li Y, Wang M, Yue M, Bai L, Bian J, Hao W, Sun J, Zhang S and Liu H: Increased AT2R expression is induced by AT1R autoantibody via two axes, Klf-5/IRF-1 and circErbB4/miR-29a-5p, to promote VSMC migration. Cell Death Dis. 11(432)2020.PubMed/NCBI View Article : Google Scholar | |
|
Fatima N, Patel SN and Hussain T: Angiotensin II type 2 receptor: A target for protection against hypertension, metabolic dysfunction, and organ remodeling. Hypertension. 77:1845–1856. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Alenina N and dos Santos RAS: Angiotensin-(1-7) and Mas. In: The Protective Arm of the Renin Angiotensin System (RAS). Elsevier, pp155-159, 2015. | |
|
Pawlik MW, Kwiecien S, Ptak-Belowska A, Pajdo R, Olszanecki R, Suski M, Madej J, Targosz A, Konturek SJ, Korbut R and Brzozowski T: The renin-angiotensin system and its vasoactive metabolite angiotensin-(1-7) in the mechanism of the healing of preexisting gastric ulcers. The involvement of Mas receptors, nitric oxide, prostaglandins and proinflammatory cytokines. J Physiol Pharmacol. 67:75–91. 2016.PubMed/NCBI | |
|
Xu J, Fan J, Wu F, Huang Q, Guo M, Lv Z, Han J, Duan L, Hu G, Chen L, et al: The ACE2/angiotensin-(1-7)/Mas receptor axis: Pleiotropic roles in cancer. Front Physiol. 8(276)2017.PubMed/NCBI View Article : Google Scholar | |
|
Luo Y, Tanabe E, Kitayoshi M, Nishiguchi Y, Fujiwara R, Matsushima S, Sasaki T, Sasahira T, Chihara Y, Nakae D, et al: Expression of MAS1 in breast cancer. Cancer Sci. 106:1240–1248. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Qaradakhi T, Apostolopoulos V and Zulli A: Angiotensin (1-7) and alamandine: Similarities and differences. Pharmacol Res. 111:820–826. 2016.PubMed/NCBI View Article : Google Scholar | |
|
da Silva FA, Rodrigues-Ribeiro L, Melo-Braga MN, Passos-Silva DG, Sampaio WO, Gorshkov V, Kjeldsen F, Verano-Braga T and Santos RAS: Phosphoproteomic studies of alamandine signaling in CHO-MrgD and human pancreatic carcinoma cells: An antiproliferative effect is unveiled. Proteomics. 22(e2100255)2022.PubMed/NCBI View Article : Google Scholar | |
|
Patel VB, Zhong J-C, Grant MB and Oudit GY: Role of the ACE2/angiotensin 1-7 axis of the renin-angiotensin system in heart failure. Circ Res. 118:1313–1326. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Heyman SN, Walther T and Abassi Z: Angiotensin-(1-7)-A potential remedy for AKI: Insights derived from the COVID-19 pandemic. J Clin Med. 10(1200)2021.PubMed/NCBI View Article : Google Scholar | |
|
Hrenak J, Paulis L and Simko F: Angiotensin A/alamandine/MrgD axis: Another clue to understanding cardiovascular pathophysiology. Int J Mol Sci. 17(1098)2016.PubMed/NCBI View Article : Google Scholar | |
|
Philippe A: Unraveling the prevalence of angiotensin II type 1 receptor antibodies in hypertension. Am J Hypertens. 33:711–712. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Wagner MJ, Lyons YA, Siedel JH, Dood R, Nagaraja AS, Haemmerle M, Mangala LS, Chanana P, Lazar AJ, Wang WL, et al: Combined VEGFR and MAPK pathway inhibition in angiosarcoma. Sci Rep. 11(9362)2021.PubMed/NCBI View Article : Google Scholar | |
|
Catarata MJ, Ribeiro R, Oliveira MJ, Robalo Cordeiro C and Medeiros R: Renin-angiotensin system in lung tumor and microenvironment interactions. Cancers (Basel). 12(1457)2020.PubMed/NCBI View Article : Google Scholar | |
|
Perea Paizal J, Au SH and Bakal C: Squeezing through the microcirculation: Survival adaptations of circulating tumour cells to seed metastasis. Br J Cancer. 124:58–65. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Saman H, Raza SS, Uddin S and Rasul K: Inducing angiogenesis, a key step in cancer vascularization, and treatment approaches. Cancers (Basel). 12(1172)2020.PubMed/NCBI View Article : Google Scholar | |
|
Liu ZL, Chen HH, Zheng LL, Sun LP and Shi L: Angiogenic signaling pathways and anti-angiogenic therapy for cancer. Signal Transduct Target Ther. 8(198)2023.PubMed/NCBI View Article : Google Scholar | |
|
Pinter M and Jain RK: Targeting the renin-angiotensin system to improve cancer treatment: Implications for immunotherapy. Sci Transl Med. 9(eaan5616)2017.PubMed/NCBI View Article : Google Scholar | |
|
Brasier AR, Recinos A III and Eledrisi MS: Vascular inflammation and the renin-angiotensin system. Arterioscler Thromb Vasc Biol. 22:1257–1266. 2002.PubMed/NCBI View Article : Google Scholar | |
|
Albulescu R, Codrici E, Popescu ID, Mihai S, Necula LG, Petrescu D, Teodoru M and Tanase CP: Cytokine patterns in brain tumour progression. Mediators Inflamm. 2013(979748)2013.PubMed/NCBI View Article : Google Scholar | |
|
Liu B, Qu L and Yan S: Cyclooxygenase-2 promotes tumor growth and suppresses tumor immunity. Cancer Cell Int. 15(106)2015.PubMed/NCBI View Article : Google Scholar | |
|
Zhang RM, McNerney KP, Riek AE and Bernal-Mizrachi C: Immunity and hypertension. Acta Physiol (Oxf). 231(e13487)2021.PubMed/NCBI View Article : Google Scholar | |
|
Cao DY, Saito S, Veiras LC, Okwan-Duodu D, Bernstein EA, Giani JF, Bernstein KE and Khan Z: Role of angiotensin-converting enzyme in myeloid cell immune responses. Cell Mol Biol Lett. 25(31)2020.PubMed/NCBI View Article : Google Scholar | |
|
Perini MV, Dmello RS, Nero TL and Chand AL: Evaluating the benefits of renin-angiotensin system inhibitors as cancer treatments. Pharmacol Ther. 211(107527)2020.PubMed/NCBI View Article : Google Scholar | |
|
Wang Q, Lei X, Zhu S and Zhang S: Angiotensin-I converting enzyme inhibitors suppress angiogenesis and growth of esophageal carcinoma xenografts. Dis Esophagus. 25:757–763. 2012.PubMed/NCBI View Article : Google Scholar | |
|
Bryniarski P, Nazimek K and Marcinkiewicz J: Immunomodulatory activity of the most commonly used antihypertensive drugs-angiotensin converting enzyme inhibitors and angiotensin II receptor blockers. Int J Mol Sci. 23(1772)2022.PubMed/NCBI View Article : Google Scholar | |
|
Kunvariya AD, Dave SA, Modi ZJ, Patel PK and Sagar SR: Exploration of multifaceted molecular mechanism of angiotensin-converting enzyme 2 (ACE2) in pathogenesis of various diseases. Heliyon. 9(e15644)2023.PubMed/NCBI View Article : Google Scholar | |
|
Rosenthal T and Gavras I: Renin-angiotensin inhibition in combating malignancy: A review. Anticancer Res. 39:4597–4602. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Budiana ING, Angelina M and Pemayun TGA: Ovarian cancer: Pathogenesis and current recommendations for prophylactic surgery. J Turk Ger Gynecol Assoc. 20:47–54. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Martins FC, Couturier DL, Paterson A, Karnezis AN, Chow C, Nazeran TM, Odunsi A, Gentry-Maharaj A, Vrvilo A, Hein A, et al: Clinical and pathological associations of PTEN expression in ovarian cancer: A multicentre study from the ovarian tumour tissue analysis consortium. Br J Cancer. 123:793–802. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Huang L, Guo Z, Wang F and Fu L: KRAS mutation: From undruggable to druggable in cancer. Signal Transduct Target Ther. 6(386)2021.PubMed/NCBI View Article : Google Scholar | |
|
Fujimoto Y, Morita TY, Ohashi A, Haeno H, Hakozaki Y, Fujii M, Kashima Y, Kobayashi SS and Mukohara T: Combination treatment with a PI3K/Akt/mTOR pathway inhibitor overcomes resistance to anti-HER2 therapy in PIK3CA-mutant HER2-positive breast cancer cells. Sci Rep. 10(21762)2020.PubMed/NCBI View Article : Google Scholar | |
|
Harrington BS and Annunziata CM: NF-κB signaling in ovarian cancer. Cancers (Basel). 11(1182)2019.PubMed/NCBI View Article : Google Scholar | |
|
Zhang T, Ma C, Zhang Z, Zhang H and Hu H: NF-κB signaling in inflammation and cancer. MedComm (2020). 2:618–653. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Regulska K, Michalak M, Kolenda T, Kozłowska-Masłoń J, Guglas K and Stanisz B: Angiotensin-converting enzyme inhibitors for ovarian cancer? -A new adjuvant option or a silent trap. Rep Pract Oncol Radiother. 28:551–564. 2023.PubMed/NCBI View Article : Google Scholar | |
|
Beyazit F, Ayhan S, Celik HT and Gungor T: Assessment of serum angiotensin-converting enzyme in patients with epithelial ovarian cancer. Arch Gynecol Obstet. 292:415–420. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Harding BN, Delaney JA, Urban RR and Weiss NS: Post-diagnosis use of antihypertensive medications and the risk of death from ovarian cancer. Gynecol Oncol. 154:426–431. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Piškur I, Topolovec Z, Bakula M, Zagorac I, Milić Vranješ I and Vidosavljević D: Expression of vascular endothelial growth factor-A (VEGF-A) in adenocarcinoma and squamous cell cervical cancer and its impact on disease progression: Single institution experience. Medicina (Lithuania). 59(1189)2023.PubMed/NCBI View Article : Google Scholar | |
|
Zhou Y, Shu C and Huang Y: Fibronectin promotes cervical cancer tumorigenesis through activating FAK signaling pathway. J Cell Biochem. 120:10988–10997. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Zhou J, Yi Q and Tang L: The roles of nuclear focal adhesion kinase (FAK) on cancer: A focused review. J Exp Clin Cancer Res. 38(250)2019.PubMed/NCBI View Article : Google Scholar | |
|
Mrozik KM, Blaschuk OW, Cheong CM, Zannettino ACW and Vandyke K: N-cadherin in cancer metastasis, its emerging role in haematological malignancies and potential as a therapeutic target in cancer. BMC Cancer. 18(939)2018.PubMed/NCBI View Article : Google Scholar | |
|
Spada S, Tocci A, Di Modugno F and Nisticò P: Fibronectin as a multiregulatory molecule crucial in tumor matrisome: From structural and functional features to clinical practice in oncology. J Exp Clin Cancer Res. 40(102)2021.PubMed/NCBI View Article : Google Scholar | |
|
Garvin AM, De Both MD, Talboom JS, Lindsey ML, Huentelman MJ and Hale TM: Transient ACE (angiotensin-converting enzyme) inhibition suppresses future fibrogenic capacity and heterogeneity of cardiac fibroblast subpopulations. Hypertension. 77:904–918. 2021.PubMed/NCBI View Article : Google Scholar | |
|
McLachlan CS: The angiotensin-converting enzyme 2 (ACE2) receptor in the prevention and treatment of COVID-19 are distinctly different paradigms. Clin Hypertens. 26(14)2020.PubMed/NCBI View Article : Google Scholar | |
|
Wang R, Xu J, Wu J, Gao S and Wang Z: Angiotensin-converting enzyme 2 alleviates pulmonary artery hypertension through inhibition of focal adhesion kinase expression. Exp Ther Med. 22(1165)2021.PubMed/NCBI View Article : Google Scholar | |
|
Clarke NE, Fisher MJ, Porter KE, Lambert DW and Turner AJ: Angiotensin converting enzyme (ACE) and ACE2 bind integrins and ACE2 regulates integrin signalling. PLoS One. 7(e34747)2012.PubMed/NCBI View Article : Google Scholar | |
|
Brooks SD, Smith RL, Moreira AS and Ackerman HC: Oral lisinopril raises tissue levels of ACE2, the SARS-CoV-2 receptor, in healthy male and female mice. Front Pharmacol. 13(798349)2022.PubMed/NCBI View Article : Google Scholar | |
|
Radin DP, Krebs A, Maqsudlu A and Patel P: Our ACE in the HOLE: Justifying the use of angiotensin-converting enzyme inhibitors as adjuvants to standard chemotherapy. Anticancer Res. 38:45–49. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Stavropoulos A, Varras M, Vasilakaki T, Varra VK, Tsavari A, Varra FN, Nonni A, Kavantzas N and Lazaris AC: Expression of p53 and PTEN in human primary endometrial carcinomas: Clinicopathological and immunohistochemical analysis and study of their concomitant expression. Oncol Lett. 17:4575–4589. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Aslan O, Cremona M, Morgan C, Cheung LW, Mills GB and Hennessy BT: Preclinical evaluation and reverse phase protein Array-based profiling of PI3K and MEK inhibitors in endometrial carcinoma in vitro. BMC Cancer. 18(168)2018.PubMed/NCBI View Article : Google Scholar | |
|
Manning-Geist BL, Liu YL, Devereaux KA, Paula ADC, Zhou QC, Ma W, Selenica P, Ceyhan-Birsoy O, Moukarzel LA, Hoang T, et al: Microsatellite instability-high endometrial cancers with MLH1 promoter hypermethylation have distinct molecular and clinical profiles. Clin Cancer Res. 28:4302–4311. 2022.PubMed/NCBI View Article : Google Scholar | |
|
Erickson BK, Najjar O, Damast S, Blakaj A, Tymon-Rosario J, Shahi M, Santin A, Klein M, Dolan M, Cimino-Mathews A, et al: Human epidermal growth factor 2 (HER2) in early stage uterine serous carcinoma: A multi-institutional cohort study. Gynecol Oncol. 159:17–22. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Elnashar AT, Hassab Elnaby NED, Abdellatef AA and Salem MN: Her-2 neu expression in endometrial carcinoma. Med J Cairo Univ. 86:69–76. 2018. | |
|
Florescu MM, Pirici D, Simionescu CE, Stepan AE, Mărgăritescu C, Tudorache Ş and Ciurea RN: E-cadherin and β-catenin immunoexpression in endometrioid endometrial carcinoma. Rom J Morphol Embryol. 57:1235–1240. 2016.PubMed/NCBI | |
|
Delforce SJ, Lumbers ER, Corbisier de Meaultsart C, Wang Y, Proietto A, Otton G, Scurry J, Verrills NM, Scott RJ and Pringle KG: Expression of renin-angiotensin system (RAS) components in endometrial cancer. Endocr Connect. 6:9–19. 2017.PubMed/NCBI View Article : Google Scholar |
